Latest Period
Q4 2025
Security Snapshot
Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) Institutional Ownership
CUSIP: 687604108
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
143
Shares (Excl. Options)
52,853,940
Price
$30.31
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- ORKA on Nasdaq
- Shares outstanding
- 68,359,580
- Price per share
- $49.05
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 52,853,940
- Total reported value
- $1,602,043,688
- % of total 13F portfolios
- 0%
- Share change
- +5,589,327
- Value change
- +$170,793,609
- Number of holders
- 143
- Price from insider filings
- $49.05
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ORKA - Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 687604108.
- 143 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 143 to 36 between Q4 2025 and Q1 2026.
- Reported value moved from $1,602,043,688 to $47,706,271.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 143 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 687604108?
CUSIP 687604108 identifies ORKA - Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 687604108:
Significant Owners of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $670,272,174 | +$122,739,728 | 13,665,080 | +22% | Fairmount Funds Management LLC | 30 Apr 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | -11% | $94,411,973 | +$14,637,703 | 4,909,619 | +18% | Venrock Healthcare Capital Partners III, L.P. | 30 Sep 2025 |
| BlackRock, Inc. | 6.6% | +42% | $96,248,890 | +$29,642,149 | 3,175,483 | +45% | BlackRock, Inc. | 31 Dec 2025 |
| VIKING GLOBAL INVESTORS LP | 5.5% | $38,693,672 | 2,666,690 | VIKING GLOBAL INVESTORS LP | 17 Sep 2025 | |||
| Deep Track Capital, LP | 4.5% | -12% | $65,515,368 | +$8,023,966 | 2,161,510 | +14% | Deep Track Capital, LP | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 4.3% | -18% | $62,382,466 | +$3,409,845 | 2,058,148 | +5.8% | RTW Investments, LP | 31 Dec 2025 |
As of 31 Dec 2025, 143 institutional investors reported holding 52,853,940 shares of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA). This represents 77% of the company’s total 68,359,580 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) together control 67% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 7,261,384 | +0.05% | 0.01% | $220,092,549 |
| VR ADVISER, LLC | 6.1% | 4,148,428 | 0% | 6.2% | $125,738,853 |
| Fairmount Funds Management LLC | 5.4% | 3,705,262 | 0% | 8.5% | $112,306,491 |
| BlackRock, Inc. | 5.2% | 3,539,415 | +61% | 0% | $107,279,669 |
| VIKING GLOBAL INVESTORS LP | 3.9% | 2,666,690 | 0% | 0.21% | $80,827,374 |
| VANGUARD GROUP INC | 3.6% | 2,453,530 | +38% | 0% | $74,366,494 |
| Deep Track Capital, LP | 3.2% | 2,161,510 | -19% | 1.5% | $65,515,368 |
| RTW INVESTMENTS, LP | 3% | 2,058,148 | +5.8% | 0.62% | $62,382,466 |
| Commodore Capital LP | 2.6% | 1,753,054 | 0% | 3.5% | $53,135,067 |
| Paradigm Biocapital Advisors LP | 2.5% | 1,710,316 | 1.4% | $51,839,678 | |
| Remedium Capital Partners, LLC | 2.3% | 1,552,414 | 0% | 28% | $47,054,000 |
| PERCEPTIVE ADVISORS LLC | 2.2% | 1,476,501 | +16% | 0.82% | $44,752,745 |
| STATE STREET CORP | 2% | 1,383,847 | +112% | 0% | $41,944,403 |
| Avoro Capital Advisors LLC | 2% | 1,333,340 | 0% | 0.4% | $40,413,535 |
| Blackstone Inc. | 1.7% | 1,165,408 | +37% | 0.15% | $35,323,516 |
| Polar Capital Holdings Plc | 1.4% | 978,288 | -5.2% | 0.14% | $29,651,909 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 942,507 | +37% | 0% | $28,574,387 |
| FRANKLIN RESOURCES INC | 1.4% | 938,421 | -12% | 0.01% | $28,443,541 |
| Affinity Asset Advisors, LLC | 1.2% | 802,342 | -16% | 1.7% | $24,318,986 |
| MERCER GLOBAL ADVISORS INC /ADV | 1.1% | 745,277 | -13% | 0.03% | $22,589,346 |
| CITADEL ADVISORS LLC | 1.1% | 726,118 | +129% | 0.01% | $22,008,637 |
| Avidity Partners Management LP | 0.97% | 660,424 | 0% | 5.8% | $20,017,451 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.95% | 649,346 | +3.6% | 0% | $19,683,000 |
| Point72 Asset Management, L.P. | 0.88% | 600,000 | -42% | 0.03% | $18,186,000 |
| Woodline Partners LP | 0.84% | 574,553 | +0.04% | 0.07% | $17,414,701 |
Institutional Holders of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 972,604 | $47,706,271 | +$2,407,631 | $49.05 | 36 |
| 2025 Q4 | 52,853,940 | $1,602,043,688 | +$170,793,609 | $30.31 | 143 |
| 2025 Q3 | 45,557,412 | $875,823,009 | +$220,884,566 | $19.23 | 104 |
| 2025 Q2 | 34,429,035 | $385,950,468 | +$30,431,109 | $11.21 | 81 |
| 2025 Q1 | 31,776,517 | $326,087,518 | -$21,453,560 | $10.26 | 70 |
| 2024 Q4 | 31,038,311 | $606,624,310 | +$125,781,752 | $19.39 | 66 |
| 2024 Q3 | 24,559,501 | $604,174,991 | +$603,646,384 | $24.51 | 41 |